High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma

Elevated expression of ECT2 predicts unfavorable prognosis in patients with colorectal cancer

(2015) Yang Luo et al.   BIOMEDICINE & PHARMACOTHERAPY

Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer

(2015) Ruifang Sun et al.   TUMOR BIOLOGY

ECT2amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma

(2014) Yoshihiko Murata et al.   CANCER SCIENCE

Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines

(2014) Alice Pasini et al.   Translational Oncology

CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data

(2013) Gabriela Bindea et al.   BIOINFORMATICS

Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)

(2013) Gerald Schmid-Bindert   Targeted Oncology

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

(2013) Melissa S. Cline et al.   Scientific Reports

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses

(2012) W. E. Pierceall et al.   ANNALS OF ONCOLOGY

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Oncogenic Activity of Ect2 Is Regulated through Protein Kinase Cι-mediated Phosphorylation

(2010) Verline Justilien et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ect2 links the PKCι–Par6α complex to Rac1 activation and cellular transformation

(2009) V Justilien et al.   ONCOGENE

Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression

(2008) D. Hirata et al.   CLINICAL CANCER RESEARCH